← All trials
NCT05477160
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- Jul 28, 2022
- Last posted
- Aug 11, 2022
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Astria Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.